Dr Ibrahim Hamza Kankia is a lecturer and researcher in the Department of Biochemistry, UmaruMusa Yar’adua University, Katsina, Nigeria. He is a mentor and his teaching method endears him to students. His research prowess cuts across Biochemistry, Microbiology, Molecular Biology, Biotechnology and Pharmacology. He is an expertise in Cancer Research, Cell Biology and Systems Biology.
Dr Kankia holds B.Sc., M.Sc. and Ph.D. degrees in Biochemistry, Biomedical Sciences and Molecular and Cellular Pharmacology from UDU Sokoto, Nigeria, University of Chester, UK and Abertay University, Dundee, UK respectively. His area of specialisation is molecular, biochemical, biotechnological and pharmacological approaches to improving breast and ovarian cancer therapy.
Publications and Conference presentations
Dr Kankia has quality articles in a high impact factorjournals;he has presented papers at both National and International Conferences. The various conferences he attended has led to networking, meeting the keynote speakers for advice and feedback on his research work, creating connections with researchers of similar interests, and collaborations for subsequent future research grants. These have indeed brought an improvement and incremental growth in his approach to do things in the broader manner.
Recent Publications by Dr Kankia
- Kankia, I. H., Khalil, H. S., Langdon, S. P., Moult, P. R., Bown, J. L., &Deeni, Y. Y. (2017). NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib. Oxidative Medicine and Cellular Longevity, 2017.
- Khalil, H. S., Langdon, S. P., Kankia, I. H., Bown, J., &Deeni, Y. Y. (2016). NRF2 regulates HER2 and HER3 signaling pathway to modulate sensitivity to targeted immunotherapies. Oxidative medicine and cellular longevity, 2016.
- Kankia, H.,&Safiyya, Y (2015). Pregnancy complications and mental health related problems associated with type 2 diabetic patients attending general hospital Katsina, Nigeria. Google Scholar.
- Kankia, H. I. (2014). Phytochemical screening and antibacterial activities of leaf extracts of Terminalia catappa (Umbrella tree). International Journal of Science and Research (IJSR), 3, 12.
Dr Kankia’s research focus on understanding the mechanism of regulation of NRF2 and EGFRs as novel approaches to improving breast and ovarian cancer therapy. The nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) is a transcription factor and the master regulator of the antioxidant response pathway. It drives both basal and oxidative stress-induced transcription of a battery of phases I, II, and III detoxification enzymes and cytoprotective genes as well as other genes of the metabolic and signal transduction pathways. The epidermal growth factor receptors (EGFRs) kinase family are regulators of cellular proliferation, differentiation, and survival, as well as being factors leading to cancer initiation, maintenance, and progression. Both NRF2 and EGFRs are recognised agents in cellular proliferation and adaptation to reactive oxygen species (ROS) and in conferring therapeutic resistance to cancers. Thus, Dr Kankia’s research, focus on exploring new mechanism of crosstalk between NRF2 and EGFRs pathways, so as to open up a novel avenues of targeting and manipulating the NRF2 and EGFRs pathways to sensitise resistant breast and ovarian cancer cells to targeted therapeutics.
Dr Kankia is member of several International and National Scientific Societies including Royal Society of Biology (RSB), American Society for Biochemistry and Molecular Biology (ASBMB) and Nigerian Society of Biochemistry & Molecular Biology (NSBMB). He also collaborates with Dr Yusuf Deeni from Abertay University Dundee, UK, Dr Simon Langdon from Edinburgh University, UK and Dr Hilal S. Khalil from Brookdale University Hospital, USA
Dr Kankia’spapers gotrecognition, read and cited in both Google scholar and Researchgate
Mobile Number +2348066225056.